The University of Texas MD Anderson Cancer Center-led team found that V-domain immunoglobulin suppressor of T cell activation (VISTA) is preferentially expressed at high levels in pancreatic cancer, when compared with melanoma tumors. The researchers’ studies also provided a detailed analysis of immune infiltration in primary and metastatic pancreatic cancers, in comparison with melanoma, which could further help to direct immunotherapy strategies against pancreatic cancer treatment. Read more. . .
While current immune checkpoint inhibitor therapies are largely ineffective against pancreatic cancer, scientists in the U.S. have now identified an immune checkpoint molecule that could represent a promising immunotherapeutic target for this tumor type.